T1	Lab_value_phrase 757 895	therefore, when the patient was age 10 years, infliximab (initially at 5 mg/kg increased to 10 mg/kg IV every 4 to 6 weeks) was initiated.
T2	Lab_value 828 835	5 mg/kg
T3	Diagnostic_procedure 803 813	infliximab
T4	Lab_value_phrase 1046 1100	Adalimumab (24 mg/m2 every 2 weeks) was then initiated
T5	Lab_value 1058 1066	24 mg/m2
T6	Diagnostic_procedure 1046 1056	Adalimumab
T7	Lab_value_phrase 1105 1164	the dosage of methotrexate (15 mg/m2/weekly) was increased.
T8	Lab_value 1133 1148	15 mg/m2/weekly
T9	Diagnostic_procedure 1109 1115	dosage
T10	Lab_value_phrase 1206 1239	Mycophenolate mofetil (750 mg/m2)
T11	Lab_value 1229 1238	750 mg/m2
T12	Diagnostic_procedure 1206 1227	Mycophenolate mofetil
T13	Lab_value_phrase 1244 1309	then abatacept (10 mg/kg/month IV) were sequentially administered
T14	Lab_value 1260 1274	10 mg/kg/month
T15	Diagnostic_procedure 1275 1277	IV
T16	Lab_value_phrase 1621 1681	with an average of 3 boluses/month for 6 consecutive months.
T17	Lab_value 1640 1655	3 boluses/month
T18	Diagnostic_procedure 1629 1636	average
T19	Lab_value_phrase 1748 1832	we initiated a trial of IL-1 antibody administration (2 mg/kg/month of canakinumab).
T20	Lab_value 1802 1815	2 mg/kg/month
T21	Diagnostic_procedure 1777 1785	antibody
T22	Lab_value_phrase 1986 2041	low-dose prednisone (0.2 mg/kg/day) remained unchanged.
T23	Lab_value 2007 2020	0.2 mg/kg/day
T24	Diagnostic_procedure 1995 2005	prednisone
